Chen HJ, et al. - In order to evaluate the effectiveness and safety of bevacizumab combined with antimetabolite as an adjunctive therapy in primary trabeculectomy for glaucoma, this trial was conducted. Compared with the use of antimetabolite alone, a combination of bevacizumab (1.25 mg/mL) with a regular concentration of antimetabolite did not demonstrate more benefit or harm. Between the experimental treatment group and the conventional treatment group, no significant differences in complete success rates, qualified success rates, postoperative complications, and surgical interventions were noted.